Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tarsus Pharmaceuticals (TARS)
NASDAQ:TARS
RESEARCH TOOLSreports
Holding TARS?
Track your performance easily
Earnings Data
Report Date
Mar 17, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.76Last Year’s EPS
-1.31Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Aug 04, 2021
|% Change Since: 18.80%
|Next Earnings Date:May 11, 2021
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in product sales, expansion of the sales force, and positive clinical trial data, leading to increased market coverage and financial strength. However, challenges such as the seasonal slowdown, potential financial impacts from the Medicare donut hole, and uncertainties in the European market were also discussed.Company Guidance
During Tarsus' Q3 2024 earnings call, the company reported impressive growth with over $48 million in XDEMVY net product sales, driven by more than 41,000 bottles delivered to patients. The sales force expanded from approximately 100 to 150, contributing to a meaningful increase in prescriptions among eye care professionals (ECPs). The call highlighted a direct-to-consumer campaign launch and the securing of Medicare contracts, resulting in coverage for over 80% of patient lives. Additionally, groundbreaking data from the Ersa and Rhea trials were presented, showing significant improvements in meibomian gland disease (MGD) symptoms, which are expected to expand the patient base by 1.5 million. For Q4 2024, Tarsus anticipates delivering 50,000 to 55,000 bottles, with a gross-to-net discount projected between 42% and 46%. The company ended Q3 with $317 million in cash and marketable securities, positioning it strongly for future growth.Record XDEMVY Net Product Sales
Achieved more than $48 million in XDEMVY net product sales with over 41,000 bottles delivered to patients, marking the most successful quarter to date.
Expansion of Sales Force
Sales force expanded from approximately 100 to 150, leading to increased prescription volume and engagement with eye care professionals (ECPs).
Positive Meibomian Gland Disease Data
Groundbreaking data presented, showing statistically significant improvements in MGD symptoms for patients with Demodex blepharitis, potentially expanding the patient base by 20%.
Successful Direct-to-Consumer Campaign
Launched a direct-to-consumer campaign on streaming television, resulting in positive early feedback and increased website engagement.
Increased Insurance Coverage
Secured additional commercial coverage and the remaining large Medicare contracts, now covering more than 80% of patient lives.
Strong Financial Position
Ended the third quarter with $317 million in cash and marketable securities, with gross margins remaining strong at approximately 93%.
Pipeline Advancements
Progress in pipeline with potential approval in Europe by the second half of 2027 and advancing TP-04 for rosacea and TP-05 for Lyme disease prevention to the FDA by year-end.
---
TARS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TARS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 13, 2024 | $46.50 | $46.65 | +0.32% |
| Aug 08, 2024 | $23.61 | $26.85 | +13.72% |
| May 08, 2024 | $37.35 | $34.04 | -8.86% |
| Feb 27, 2024 | $33.16 | $39.22 | +18.28% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Tarsus Pharmaceuticals (TARS) report earnings?
Tarsus Pharmaceuticals (TARS) is schdueled to report earning on Mar 17, 2025, TBA Not Confirmed.
What is Tarsus Pharmaceuticals (TARS) earnings time?
Tarsus Pharmaceuticals (TARS) earnings time is at Mar 17, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TARS EPS forecast?
TARS EPS forecast for the fiscal quarter 2024 (Q4) is -0.76.
---